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Abstract 
Pathological  cardiac  hypertrophy  induced  by  adrenergic  overactivation  can  subsequently 
develop to heart failure which remains as a leading cause of mortality worldwide. Tanshinone 
IIA is a lipid-soluble pharmacologically active compound extracted from the rhizome of the 
Chinese herb Salvia miltiorrhiza, a well-known traditional Chinese medicine used for the 
treatment of cardiovascular disorders. However, little is know about the effect of Tanshinone 
IIA on cardiac hypertrophy. The present study was aimed to investigate whether Tanshinone 
IIA prevents cardiac hypertrophy induced by isoproterenol (ISO) and to clarify its possible 
mechanisms. Cardiomyocytes hypertrophy was induced by ISO 10 μM for 48 h with or 
without Tanshinone IIA 10, 30, 100 μM pretreatment, and evaluated by determining the cell 
size and the expression of ANP, BNP, β-MHC, Calcineurin, and NFATc3 by real-time PCR 
and western blot. We found that Tanshinone IIA pretreatment attenuated the enlargement of 
cell surface area induced by ISO in cultured cardiomyocytes. The mRNA level of ANP, BNP 
and β-MHC was obviously elevated in ISO-treated cardiac cells, which was effectively inhib-
ited by Tanshinone IIA. Moreover, we found that Tanshinone IIA pretreatment could prevent 
the augment of intracellular calcium transient in ISO-treated cardiomyocytes. The further 
study revealed that Calcineurin, NFATc3, ANP, BNP and β-MHC proteins were upregulated 
by ISO in ventricular myocytes, and Tanshinone IIA pretreatment significantly attenuate the 
increased expression of Calcineurin, NFATc3, ANP, BNP and β-MHC proteins. In summary, 
Tanshinone IIA attenuated cardiomyocyte hypertrophy induced by ISO through inhibiting 
Calcineurin/NFATc3 pathway, which provides new insights into the pharmacological role and 
therapeutic mechanism of Tanshinone IIA in heart diseases. 
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Introduction 
Pathological  cardiac  hypertrophy  is  a  major 
cause  of  morbidity  and  mortality  of  cardiovascular 
diseases all over the world [1-3]. Ventricular myocar-
dium in response to  a variety of  pathologic stimuli Int. J. Biol. Sci. 2011, 7 
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such as adrenergic overactivation will undergo a hy-
pertrophic growth characterized by the increased cell 
size and activation of numerous fetal cardiac genes so 
as to compensate for the decreased function of injured 
hearts [4]. However, sustained myocardial hypertro-
phy  can  result  in  the  functional  decompensation, 
electrophysiological  remodeling,  cardiac  fibrosis, 
sudden  death  or  heart  failure  [5].  The  calcineu-
rin/nuclear  factor  of  activated  T  cells  (NFATc)  sig-
naling pathway has been shown to play an essential 
role  in  pathological  cardiac  hypertrophy  [1,  3].  Ac-
cordingly,  preventing  the  activation  of  calcineu-
rin/NFATc  signal  pathway  is  suggested  as  an  im-
portant strategy for the treatment of myocardial hy-
pertrophy.  
Danshen,  the  dry  root  and  rhizome  of  Salvia 
miltiorrhiza Bge (Labiatae), was widely used in ther-
apeutic  remedies  in  China  and  other  countries  [6]. 
Many clinical studies indicated that Danshen and its 
preparations  could  treat  coronary  artery  diseases, 
myocardial  infarction,  liver  malfunction,  etc  [6-9]. 
Tanshinone  IIA  (Tan  IIA)  is  isolated  from  Salvia 
miltiorrhiza  and  one  of  the  main  ingredients  of 
Danshen for cardioprotective effects [10]. Tanshinone 
IIA was shown to exert beneficial effects on cardio-
vascular  system  with  minimal  reported  side  effects 
[11-15]. For example, Tanshinone IIA prevented en-
dothelial cell damage through its anti-oxidant effect 
[11-12] and protected cardiomyocytes against oxida-
tive stress-triggered damage and apoptosis [13]. Our 
previous studies also uncovered that Tanshinone IIA 
protected  rats  against  sudden  cardiac  death  due  to 
lethal  arrhythmias  via  repression  of  microRNA-1. 
However, little is known about whether Tanshinone 
IIA  can  prevent  ISO-induced  cardiac  hypertrophy. 
The present study is aimed to determine the preven-
tive  role  of  Tanshinone  IIA  in  ISO-induced  cardiac 
hypertrophy  and  to  clarify  its  underlying  mecha-
nisms.  
 
Materials and Methods 
Isolation and culture of cardiomyocytes 
The procedure to culture neonatal rat ventricular 
myocytes  (NRVMs)  is  just  as  described  previously 
[16]. Briefly, the hearts of neonatal rats were rapidly 
removed. Both ventricles were cut into l to 2 mm3 and 
dissociated in 0.25% trypsin at 37 °C for 1-2 min. Cell 
suspensions  were  shifted  out  and  neutralized  with 
cell culture medium. Cardiac tissues were trypsinized 
until  the  tissues  disappeared  and  cell  suspensions 
were collected. Then all suspensions were pelleted by 
centrifugation at 2000 rpm for 180 s. The isolated cells 
were then resuspended in DMEM (Hyclone Labora-
tories)  supplemented  with  10%  fetal  bovine  serum 
(Gibco) and penicillin (100 U/ml)/streptomycin (100 
U/ml), transferred into culture flask and cultured at 
37 °C in humid air with 5% CO2. After 90 min for fi-
broblast  adherence,  neonatal  cardiomyocytes  were 
plated into 6-well plate at a density of 3×105 cells per 
well. After 48 h culture, NRVMs were treated by ISO 
for 48 h in the absence or presence of Tanshinone IIA. 
Measurement of cell surface area 
Cultured  cardiomyocytes  were  fixed  with  4% 
paraformaldehyde for 0.5 h. Then the cell membrane 
was  penetrated  by  0.4%  Triton  X-100  for  1h  and 
blocked  by  goat  serum  for  1  h.  Followed  by  an-
ti-sarcomeric actin antibody (Sigma, St. Louis, MO), at 
4°C  overnight,  subsequently  incubation  with 
FITC-conjugated  goat  anti-mouse  antibody  for  1h. 
Immunofluorescence was  analyzed under a fluores-
cence  microscope  (Nikon  80i).  Cell  surface  was 
measured by Image-Pro Plus Data Analysis Software. 
Quantification  of  cell  surface  area  by  measuring  60 
random cells from three experiments, and the average 
value was used for analysis. 
Quantitative Real-time PCR 
Total RNA was extracted from cultured neonatal 
cardiomyocytes using TRIZOL reagent. To detect the 
level of ANP, BNP and β-MHC mRNAs, quantitative 
Real-time PCR was performed on ABI 7500 fast Real 
Time  PCR  system  (Applied  Biosystems,  USA).  The 
Real-time PCR primer sequences for ANP were for-
ward: 5′-CTCCGATAGATCTGCCCTCTTGAA-3′ and 
reverse:  5′-GGTACCGGAAGCTGTTGCAGCCTA-3′. 
The  primer  sequences  for  BNP  were  forward 
5′-TTGGGCAGAAGATAGACCGGAT-3′ and reverse 
5′-GGTCTTCCTAAAACAACCTCA-3′;  The  primer 
sequences  for  β-MHC  were  forward: 
5'-AACCTGTCCAAGTTCCGCAAGGTG-3′  and  re-
verse  GAGCTGGGTAGCACAAGAGCTACT-3′;  The 
sequences of GAPDH primers were forward primer: 
5′-TCTACATGTTCCAGTATGACTC-3′  and  reverse: 
5′-ACTCCACGACATACTCAGCACC-3′.  GAPDH 
was used as an internal control.  
Measurement of intracellular calcium transient 
Cultured cells were stained by Fluo-3/AM at 37 
°C for 45 min, and then washed with standard exter-
nal  solution  contain  Ca2+  for  3  times.  Fluorescent 
changes  of  Fluo-3/AM-loaded  cells  were  detected 
using laser scanning Confocal microscope (Olympus 
FV-300) with 488 nm for excitation from an argon ion 
laser and 530 nm for emission. The fluorescent inten-
sities before (FI0) and after (FI) KCl 30 mM admin-
istration were both recorded. Qualitative changes in Int. J. Biol. Sci. 2011, 7 
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the increase of intracellular Ca2+ level were inferred 
from the ratio of FI/FI0. 
Western Blot 
The  protein  samples  were  extracted  from  the 
whole  cells  with  the  procedures  as  previously  de-
scribed [3]. Cardiac cells were also lysed with stand-
ard sample buffer, and then to broke the cells by ul-
trasound. For deliver protein sufficiently, the mixed 
liquor was kept on the ice for 30 min. The mixed liq-
uor  was  centrifuged  and  then  the  supernatant  was 
collected.  Protein  concentration  was  determined  in 
the supernatant using ABC as recommended by the 
manufacturer. After boiling the samples for 5 min, the 
protein  samples  were  fractionated  by  SDS-PAGE 
(10%-15%  polyacrylamide  gels)  and  transferred  to 
PVDF  membrane  (Millipore,  Bedford,  MA).  The 
membranes were blocked with milk powder at room 
temperature for 2 h. The membranes were incubated 
with  primary  antibodies  ANP,  BNP,  β-MHC  (Santa 
Cruz  Biotechnology  Inc.  USA),  calcineurin  (Santa 
Cruz  Biotechnology  Inc.  USA)  and  NFATc3  (Santa 
Cruz  Biotechnology  Inc.  USA)  at  4  °C  overnight, 
washed,  and  incubated  with  a  secondary  rabbit  or 
mouse  polyclonal  and  purchased  from  Santa  Cruz 
Biotechnology for 1 h at room temperature. Western 
blot bands were quantified using Odyssey v1.2 soft-
ware by measuring the band intensity (area×OD) for 
each group and normalizing to GAPDH as an internal 
control. 
Statistical analysis 
All  experimental  data  were  presented  as  the 
mean ± SEM. ANOVA or t-test was used to compare 
mean values using SPSS 13.0 software. Values of p < 
0.05 were considered statistically significant. 
Results 
Tanshinone IIA attenuated ISO-induced the in-
crease of cell surface area 
Myocardial  hypertrophy  was  induced  by  ex-
posing neonatal cardiomyocytes to ISO 10 μM for 48 
h. Hypertrophic growth was assayed by the staining 
of a-sarcomeric actinin protein in cultured cardiomy-
ocytes. As shown in Fig. 1A, ISO 10 μM significantly 
increased cell surface area of cardiac myocytes. Fur-
thermore,  Tanshinone  IIA  10,  30  and  100  μM  pre-
treatment markedly inhibited the increase of cell sur-
face  area  in  ISO-treated  cardiomyocytes,  indicating 
that Tanshinone IIA played a preventive role in car-
diac hypertrophy induced by ISO.  
 
Figure 1. Effect of Tanshinone IIA on ISO-induced the hypertrophic growth in cardiomyocytes. (A) Tanshinone IIA 10, 30 
and 100 μM attenuated ISO-induced hypertrophic growth evaluated by the visualization of sarcomere organization; (B) 
ISO-induced the enlargement of cell surface area was inhibited by Tanshinone IIA 10, 30 and 100 μM. Data are expressed as 
mean ± SEM for examination of 60 random cells from four experiments. * P < 0.05 vs. Control, # P < 0.05 vs. ISO. (Scale bar, 
20μm) Int. J. Biol. Sci. 2011, 7 
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Tanshinone IIA reversed ISO-induced the in-
crease of ANP, BNP and β-MHC at mRNA and 
protein levels 
To  confirm  the  inhibitory  effect  of  Tanshinone 
IIA  on  cardiomyocytes  hypertrophy,  we  further  in-
vestigated  the  effects  of  Tanshinone  IIA  on 
ISO-induced the expression of hypertrophic markers 
atrial  natriuretic  peptide  (ANP),  brain  natriuretic 
peptide (BNP) and β-myosin heavy chain (β-MHC) in 
cultured  cardiomyocytes.  Real-time  quantitative 
RT-PCR  analysis  showed  ISO  induced  a  significant 
increase of ANP, BNP and β-MHC mRNAs by over 
2-fold in cardiac cells (Fig. 2A-2C). Tanshinone IIA 30 
and 100 μM obviously inhibited ISO-induced the up-
regulation of these hypertrophic markers.  
To  further  confirm  the  preventive  effect  of 
Tanshinone IIA on ISO-induced cardiac hypertrophy, 
we  next  evaluated  effect  of  Tanshinone  IIA  on 
ISO-induced the changes of ANP, BNP and β-MHC 
proteins (Fig. 2D). The expression of ANP, BNP and 
β-MHC proteins was also upregulated in the presence 
of ISO 10 μM for 48 h (Fig. 2E-2G). Tanshinone IIA 
obviously  reversed  the  upregulation  of  ANP,  BNP 
and β-MHC proteins in ISO-treated cardiac cells. 
Effects of Tanshinone on ISO-induced enhance-
ment of intracellular calcium transient 
It  is  well  known  that  cardiac  hypertrophic  re-
sponses are triggered by the elevation of intracellular 
Ca2+ level. To reveal the detailed mechanism for the 
preventive effects of Tanshinone IIA on heart hyper-
trophy,  we  observed  whether  intracellular  calcium 
transient  was  involved  in  the  beneficial  actions  of 
Tanshinone  IIA.  A  typical  elevation  of  intracellular 
Ca2+ level after KCl (30 mM)-induced membrane de-
polarization  is  shown  in  Fig.3A.  As  illustrated  in 
Fig.3B,  ISO  incubation  significantly  enhanced  the 
amplitude  of  intracellular  calcium  transient,  which 
was obviously abolished by Tanshinone IIA 100 μM.   
 
 
Figure 2. Effect of Tanshinone IIA on ISO-induced the increased expression of ANP, BNP and β-MHC mRNAs and pro-
teins. (A), (B) and (C) The mRNA levels of hypertrophic markers ANP, and BNP, and β-MHC was analyzed by qRT-PCR. 
The cardiomyocytes treated with Tanshinone IIA 30 and 100 μM exhibited a reduction of ANP, BNP and β-MHC mRNAs 
level in ISO-treated cells. (D) The expression of ANP, BNP and β-MHC proteins in ISO-treated cardiomyocytes in the 
absence and presence of Tanshinone IIA 100 μM. (E), (F) and (G) The expression of ANP, BNP and β-MHC proteins were 
significantly increased in the cardiomyocytes treated with ISO for 48h compared with control cells, which was significantly 
inhibited by Tanshinone IIA 100 μM pretreatment. Data are expressed as mean ± SEM for three individual experiments. * P 
< 0.05 vs. Control, # P < 0.05 vs. ISO. Int. J. Biol. Sci. 2011, 7 
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Figure 3. Effects of Tanshinone IIA on ISO-induced the rise of intracellular calcium level in neonatal cardiomyocytes. ISO 
enhanced the intracellular calcium transient induced by KCl-induced membrane depolarization, which was effectively re-
stricted by Tanshinone IIA 100 μM. Data are expressed as mean±SEM for four individual experiments. * P < 0.05 vs. Control, 
# P < 0.05 vs. ISO. Data are expressed as mean ± SEM for 60 cells from at least three individual experiments. * P < 0.05 vs. 
Control, # P < 0.05 vs. ISO. 
 
 
Figure 4. Effects of Tanshinone IIA on the expression of calcineurin and NFATc3 proteins in ISO-induced cardiac hyper-
trophy. (A) A representative experiment of the expression of calcineurin and NFATc3 proteins in ISO-treated cardio-
myocytes  in  the  absence  and  presence  of  Tanshinone  IIA  100 μM.  (B)  Tanshinone  IIA  had  inhibitory  influences  on 
ISO-induced the upregulation of calcineurin in ventricular myocytes. (C) ISO-induced the increase of NFATc3 protein in 
cardiac cells was obviously reversed by Tanshinone IIA. Data are expressed as mean ± SEM for four individual experiments. 
* P < 0.05 vs. Control, # P < 0.05 vs. ISO. 
 
Tanshinone IIA inhibited the upregulation of 
calcineurin and NFATc3 
Calcineurin/NFATc3  signal  pathway  plays  a 
crucial  role  in  cardiac  hypertrophy.  We  further  ex-
amined whether Tanshinone IIA prevented myocar-
dial  hypertrophy  in  a  calcineurin/NFATc3- 
dependent  pathway.  In  accordance  to  previous  re-
ports, we also confirmed that ISO-treated cardiomy-
ocytes exhibited a considerably increased expression 
of calcineurin and NFATc3 proteins compared with 
control  cells  (Fig.  4A-4C).  Tanshinone  IIA  100  μM 
obviously  reversed  the  upregulation  of  calcineurin 
and  NFATc3  proteins  in  ISO-treated  cardiac  cells. 
These suggest that calcineurin/NFATc3 signal path-
way  also  contributes  to  the  preventive  effects  of 
Tanshinone IIA on cardiac hypertrophy. Int. J. Biol. Sci. 2011, 7 
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Discussion 
The  present  study  mainly  revealed  that 
Tanshinone IIA could protect against cardiac hyper-
trophy  induced  by  ISO  by  inhibiting  calcineu-
rin/NFATc3  signal  pathway,  which  yield  new  un-
derstanding of the therapeutic effects of Tanshinone 
IIA on pathological myocardial remodeling. 
Pathological myocardial hypertrophy as a con-
sequence of the maladaptive alterations in many heart 
diseases  is  an  important  risk  factor  for  subsequent 
cardiac  morbidity  and  mortality.  Although  initially 
beneficial, sustained cardiac hypertrophy can lead to 
decompensation and heart failure. Adrenergic over-
activation has been used to induce cardiac hypertro-
phy  and  caused  cardiac  fibrosis  in  vivo  or  in  vitro 
[17-19]. The Ca2+-activated Ser/Thr protein phospha-
tase calcineurin and the downstream transcriptional 
effectors of calcineurin, NFATcs, have been implicat-
ed  as  a  key  signaling  pathway  in  the  hypertrophic 
response of the myocardium [1, 3]. Targeted depletion 
of calcineurin activity showed an obvious reduction of 
myocardium  hypertrophy  in  mice  subjected  to  ISO 
infusion  [20].  Furthermore,  mice  with  targeted  dis-
ruptions  of  NFATc3  demonstrated  a  significant  re-
duction in calcineurin-induced cardiac hypertrophy, 
which  indicated  NFATc3  is  required  for  calcineu-
rin-regulated  hypertrophic  responses  [21].  Recently, 
microRNAs  were  also  shown  involved  in 
ISO-induced cardiac hypertrophy [22-23]. The forced 
expression of miR-23 could lead to cardiac hypertro-
phy by inhibiting MuRF1, an anti-hypertrophic pro-
tein. Though plenty of progress has been made in the 
understanding of molecular mechanism of patholog-
ical  cardiac  hypertrophy,  the  effective  therapeutic 
drugs for restoring heart functions are still lacking.  
Danshen is extracted from the dried root or rhi-
zome  of  Salvia  miltiorrhiza  Bunge  and  has  been 
widely used  in the  treatment of cardiovascular dis-
eases such as myocardial infarction and myocarditis 
[11-15].  Danshen-derived  compounds  have  many 
important  pharmacological  effects  in  basic  experi-
ments and clinic, such as anti-tumor, immunoloregu-
lation  and  cardioprotective  effects,  scavenge  lipid 
radicals and so on [7, 9-10, 24]. Recently, our studies 
also  showed  that  Tanshinone  IIA  reversed  cardiac 
potassium channel remodeling after heart infarction 
through  depressing  SRF-induced  miR-1  overexpres-
sion [15]. Previous reports also revealed that angio-
tensin II-induced hypertrophic growth in cardiomy-
ocytes  was  markedly  attenuated  in  the  presence  of 
Tanshinone IIA through inhibiting the rise of  intra-
cellular calcium and c-jun expression [14], that indi-
cates  ISO  and  angiotensin  II  caused  cardiac  hyper-
trophy through different signaling pathway. Moreo-
ver, it was also demonstrated that the blockage of Ang 
II  by  losartan  and  quinapril  could  not  prevent 
ISO-induced cardiac hypertrophy [25]. Thus, in this 
study, we aimed to investigate the effects and mech-
anisms  of  Tanshinone  IIA  on  ISO-induced  cardiac 
hypertrophy.  
We found that Tanshinone IIA markedly atten-
uated  ISO-induced  the  increase  of  cell  surface  area 
and ANP, BNP and β-MHC at both mRNA and pro-
tein levels. It indicates Tanshinone IIA plays a protec-
tive  role  in  cardiac  hypertrophy  in  response  to 
pathological stimuli. It is well known that intracellu-
lar calcium level is an important hypertrophic mes-
senger. ISO promotes the release of calcium ion from 
the sarcoplasmic reticulum, thereby increasing intra-
cellular calcium level. The subsequent increase in in-
tracellular calcium level plays a potentiating role in 
cardiac  hypertrophic  growth  by  activating  several 
signalling  pathways  [26].  Previous  studies  have 
shown  that  intracellular  Ca2+/CaM-dependent  sig-
nalling  stimulated  the  expression  of  hypertrophic 
genes in cardiomyocytes through a variety of effectors 
such  as  the  protein  phosphatase  calcineurin, 
Ca2+/CaM-dependent kinase II, and NFATcs (nuclear 
factor  of  activated  T-cells)  [27].  Therefore,  the  de-
crease in intracellular calcium level is an important 
approach to prevent hypertrophic growth of cardio-
myocytes in response to pathological stimuli. In this 
study,  we  found  that  Tanshinone  IIA  inhibited  the 
increase of intracellular calcium level caused by ISO 
in  cardiac  cells.  The  calcineurin/NFATc3  pathway 
plays an important role in conveying the signals for a 
variety  of  hypertrophic  stimuli.  Increased  cystolic 
Ca2+ activates calcineurin and thereby induces nuclear 
translocation of NFAT, which is involved in the in-
duction  of  pathological  cardiac  hypertrophy  signal-
ing. In this study we demonstrated that Tanshinone 
IIA inhibited the increased expression of calcineurin 
and  NFATc3  induced  by  ISO,  which  indicates  that 
Tanshinone IIA protects against cardiac hypertrophy 
in a Calcineurin/NFATc3-dependent pathway.  
We can confirm that there are some limitations of 
this study as followed. First, we just detected the ex-
pression of total NFATc3 and did not investigate the 
translocation of NFATc3 from cytoplasmic to nucleus 
though the Calcineurin/NFATc3-dependent pathway 
that has been confirmed in previous studies [28]. Se-
cond, inhibitors or siRNA technique was not used in 
this  study  that  will  be  another  evidence  to  demon-
strate that Ca2+/Calcineurin/NFATc3 pathway is in-
volved in the regulation of ISO-induced cardiac hy-
pertrophy. Int. J. Biol. Sci. 2011, 7 
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Taken  together,  this  study  investigated  the 
therapeutic effects of Tanshinone IIA on myocardial 
hypertrophy induced by ISO. We revealed for the first 
time that Tanshinone IIA was capable of preventing 
ISO-induced hypertrophic growth in cardiomyocyte, 
which is attributed, at least partially, to its inhibition 
of  Ca2+/Calcineurin/NFATc3  pathway.  These  find-
ings  raise  the  possibility  of  developing  Tanshinone 
IIA as a therapeutic drug for cardiac hypertrophy.  
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